- Home
- ARQT vs COLL Comparison
ARQT vs COLL Comparison
Compare ARQT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- COLL
- Stock Information
- Founded
- ARQT 2016
- COLL 2002
- Country
- ARQT United States
- COLL United States
- Employees
- ARQT N/A
- COLL 197
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- COLL Health Care
- Exchange
- ARQT Nasdaq
- COLL Nasdaq
- Market Cap
- ARQT 1.1B
- COLL 1.1B
- IPO Year
- ARQT 2020
- COLL 2015
- Fundamental
- Price
- ARQT $12.68
- COLL $33.35
- Analyst Decision
- ARQT Strong Buy
- COLL Strong Buy
- Analyst Count
- ARQT 5
- COLL 5
- Target Price
- ARQT $17.00
- COLL $43.80
- AVG Volume (30 Days)
- ARQT 2.0M
- COLL 478.2K
- Earning Date
- ARQT 02-25-2025
- COLL 02-20-2025
- Dividend Yield
- ARQT N/A
- COLL N/A
- EPS Growth
- ARQT N/A
- COLL 757.11
- EPS
- ARQT N/A
- COLL 2.16
- Revenue
- ARQT $138,708,000.00
- COLL $599,245,000.00
- Revenue This Year
- ARQT $209.03
- COLL $13.20
- Revenue Next Year
- ARQT $49.00
- COLL $17.63
- P/E Ratio
- ARQT N/A
- COLL $15.47
- Revenue Growth
- ARQT 182.84
- COLL 9.62
- 52 Week Low
- ARQT $3.11
- COLL $28.39
- 52 Week High
- ARQT $16.20
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- ARQT 43.06
- COLL 62.31
- Support Level
- ARQT $13.10
- COLL $32.29
- Resistance Level
- ARQT $14.36
- COLL $33.99
- Average True Range (ATR)
- ARQT 0.99
- COLL 1.29
- MACD
- ARQT -0.32
- COLL 0.51
- Stochastic Oscillator
- ARQT 1.95
- COLL 87.40
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.